Rationale, design, and results from RENO-DEFEND 1: A randomized, dose-finding study of the selective A1 adenosine antagonist SLV320 in patients hospitalized with acute heart failure — Peter S. Pang (2011) | RDL Network
Rationale, design, and results from RENO-DEFEND 1: A randomized, dose-finding study of the selective A1 adenosine antagonist SLV320 in patients hospitalized with acute heart failure
Giovanni Targher, Marco Dauriz, Luigi Tavazzi, Pier Luigi Temporelli, Donata Lucci, Renato Urso, Gabriella Lecchi, Giancarlo Bellanti, Marco Merlo, Andrea Rossi, Aldo Maggioni
Giovanni Targher, Marco Dauriz, Cécile Laroche, Pier Luigi Temporelli, Mahmoud Hassanein, Petar Seferović, Jarosław Dróżdż, Roberto Ferrari, S.D. Anker, Andrew J.S. Coats, Gerasimos Filippatos, María G. Crespo‐Leiro, Alexandre Mebazaa, Massimo Piepoli, Aldo Maggioni, Luigi Tavazzi
Muthiah Vaduganathan, Alessandra Dei, Robert J. Mentz, Stephen J. Greene, Sadiya S. Khan, Haris Subačius, Ovidiu Chioncel, Aldo Maggioni, Marvin A. Konstam, Michele Senni, Gregg C. Fonarow, Javed Butler, Mihai Gheorghiade
Mihai Gheorghiade, Mazen Albaghdadi, Faı̈ez Zannad, Gregg C. Fonarow, Michael Böhm, Claudio Gimpelewicz, Jaco Botha, Shelley L. Moores, Eldrin F. Lewis, Henning Rattunde, Aldo Maggioni
Discussion(0)
No comments yet. Be the first to comment.